TipRanks
Go Ultimate55% OFF

Eurobio-Scientific SA (E8TN) Price & Analysis

E8TN Stock Chart & Stats

€25.90-€0.10(-0.38%)
At close: 4:00 PM EDT
EUR 22.5EUR 2522 Sep15 Oct21 Oct26 Oct
Day’s Range
EUR 25.40 - EUR 25.90
52-Week Range
EUR 19.00 - EUR 26.00
Previous Close
EUR 26.00
Volume
0
Average Volume (3M)
80
Market Cap
EUR 258.39M
Enterprise Value
EUR 203.86M
Total Cash (Recent Filing)
EUR 26.34M
Total Debt (Recent Filing)
EUR 14.74M
Price to Earnings (P/E)
37.6
Beta
0.15
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Conservative Leverage

Debt-to-equity of about 0.09 and a sizable equity buffer indicate conservative financing. This reduces balance-sheet strain and preserves flexibility to fund product development, distribution expansion, or working-capital needs through the next several quarters.

Positive Cash Generation

Positive operating and free cash flow in every period shown demonstrates that the business converts operations into internally generated funds. That supports ongoing investment and resilience, although recent deterioration means this strength should not be treated as unqualified.

Recurring Consumables Model

Sales of continuously consumed IVD tests, reagents, and laboratory consumables can create repeat purchasing, while distribution and service offerings broaden the revenue base. This supports durable customer relationships and more resilient demand across clinical and research markets.

Bears Say

Lower Margin Durability

Net margin of about 2.9% in 2025, versus exceptionally high levels in 2021–2022, shows earnings power has reset lower. Even with gross margin around 40–46%, thinner operating profitability leaves less room to absorb execution pressure or reinvest.

Weaker Free Cash Flow

Free cash flow fell about 16% year over year in 2025 and was far below 2021–2022 levels. This weakening reduces internally funded investment capacity and makes shareholder cash generation less dependable, despite remaining positive overall.

Volatile Capital Returns

Historical returns on equity have swung materially, and 2025 ROE is shown as zero. Such inconsistency makes it harder to judge the durability of capital productivity and indicates that reported earnings have not translated into stable returns for shareholders.

Eurobio-Scientific SA News

E8TN FAQ

What was Eurobio-Scientific SA’s price range in the past 12 months?
Eurobio-Scientific SA lowest stock price was €19.00 and its highest was €26.00 in the past 12 months.
What is Eurobio-Scientific SA’s market cap?
Eurobio-Scientific SA’s market cap is €258.39M.
When is Eurobio-Scientific SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eurobio-Scientific SA’s earnings last quarter?
Eurobio-Scientific SA released its earnings results on Oct 13, 2026. The company reported €0.466 earnings per share for the quarter.
Is Eurobio-Scientific SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Eurobio-Scientific SA pay dividends?
Eurobio-Scientific SA does not currently pay dividends.
What is Eurobio-Scientific SA’s EPS estimate?
Eurobio-Scientific SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eurobio-Scientific SA have?
Eurobio-Scientific SA has 10,068,279 shares outstanding.
What happened to Eurobio-Scientific SA’s price movement after its last earnings report?
Eurobio-Scientific SA reported an EPS of €0.466 in its last earnings report. Following the earnings report the stock price went up 2.479%.
Which hedge fund is a major shareholder of Eurobio-Scientific SA?
Currently, no hedge funds are holding shares in DE:E8TN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology